PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
Immune checkpoint inhibitors (CIs) have changed the landscape of tumor immunotherapy. Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and has a very poor prognosis. Due to the high invasiveness and aggressiveness of GBM, there is considerable interest in programmed...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis Group
2021-02-01
|
| Colecção: | Human Vaccines & Immunotherapeutics |
| Assuntos: | |
| Acesso em linha: | http://dx.doi.org/10.1080/21645515.2020.1782692 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|